| ²é¿´: 682 | »Ø¸´: 4 | ||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||
cainiaoduiгæ (СÓÐÃûÆø)
|
[ÇóÖú]
·ÒëÇóÖú
|
|
|
Predictive biomarkers produced by the tumor or expressed within the tumor vessels that confer sensitivity to Dll4-Notch blockade have not yet been identified. A useful starting point may be to assume thathigh levels of Dll4-Notch are correlated with sensitivity to pathway inhibition. Thus, further analysis of the expression levels of various components of the Delta-Notch signaling pathway in clinical specimens will be useful. |
» ²ÂÄãϲ»¶
293µ÷¼Á
ÒѾÓÐ3È˻ظ´
»úе¹¤³Ì264ѧ˶Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
264Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
22408 266Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
273Çóµ÷¼Á
ÒѾÓÐ43È˻ظ´
307Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
327Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
338Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
octagonchem
¾èÖú¹ó±ö (ÕýʽдÊÖ)
- Ó¦Öú: 6 (Ó×¶ùÔ°)
- ½ð±Ò: 826.7
- É¢½ð: 162
- ºì»¨: 2
- Ìû×Ó: 589
- ÔÚÏß: 76.1Сʱ
- ³æºÅ: 2602971
- ×¢²á: 2013-08-18
- ÐÔ±ð: GG
- רҵ: Ö×Áö»¯Ñ§Ò©ÎïÖÎÁÆ
5Â¥2013-10-29 17:06:28
ÃÀ²©·Òë
Òø³æ (СÓÐÃûÆø)
- ·ÒëEPI: 12
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 471.2
- ºì»¨: 4
- Ìû×Ó: 79
- ÔÚÏß: 29.6Сʱ
- ³æºÅ: 2631435
- ×¢²á: 2013-09-03
- ÐÔ±ð: MM
- רҵ: Äý¾Û̬ÎïÐÔ II £ºµç×ӽṹ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï
cainiaodui(RXMCDM´ú·¢): ½ð±Ò+1, ¶àлӦÖú£¡ 2014-01-10 01:23:01
cainiaodui(RXMCDM´ú·¢): ½ð±Ò+1, ¶àлӦÖú£¡ 2014-01-10 01:23:01
|
Predictive biomarkers produced by the tumor or expressed within the tumor vessels that confer sensitivity to Dll4-Notch blockade have not yet been identified. A useful starting point may be to assume thathigh levels of Dll4-Notch are correlated with sensitivity to pathway inhibition. Thus, further analysis of the expression levels of various components of the Delta-Notch signaling pathway in clinical specimens will be useful. ÓÉÖ×Áö¡¢ÑϸñÀ´½²ÓɶÔDll4-Notch×èÈûÃô¸ÐµÄÖ×ÁöѪ¹ÜÒýÆðµÄÔ¤²âÉúÎï±ê¼ÇÉÐδ±»È·ÈÏ¡£×î³õÓÐÒ»ÖÖÓÐÓõĹ۵ãÈÏΪ£¬¸ßˮƽµÄDll4-NotchºÍ;¾¶ÒÖÖÆµÄÃô¸ÐÐÔÓйء£Òò´Ë£¬ÁÙ´²±ê±¾ÖÐDelta-Notch ¸÷ÖÖÐźÅͨ·µÄ×é³É³É·ÖµÄ±í´ï²ã´ÎµÄ½øÒ»²½µÄ·ÖÎö½«»áÊÇÊ®·ÖÓÐÒæºÍ±ØÒªµÄ¡£ ~~~³õ´Î·Ò룬ϲ»¶·ÒëµÄÅóÓѶà¶à´Í½Ì£¬Predictive biomarkersÔÝ·ÒëΪ¡°Ô¤²âÉúÎï±ê¼Ç¡±£¬Çë×÷ÕßÈ·ÈÏÊõÓÃÀ²©·Òë2013-10-29 |
2Â¥2013-10-29 15:38:54
octagonchem
¾èÖú¹ó±ö (ÕýʽдÊÖ)
- Ó¦Öú: 6 (Ó×¶ùÔ°)
- ½ð±Ò: 826.7
- É¢½ð: 162
- ºì»¨: 2
- Ìû×Ó: 589
- ÔÚÏß: 76.1Сʱ
- ³æºÅ: 2602971
- ×¢²á: 2013-08-18
- ÐÔ±ð: GG
- רҵ: Ö×Áö»¯Ñ§Ò©ÎïÖÎÁÆ
3Â¥2013-10-29 16:39:13
octagonchem
¾èÖú¹ó±ö (ÕýʽдÊÖ)
- Ó¦Öú: 6 (Ó×¶ùÔ°)
- ½ð±Ò: 826.7
- É¢½ð: 162
- ºì»¨: 2
- Ìû×Ó: 589
- ÔÚÏß: 76.1Сʱ
- ³æºÅ: 2602971
- ×¢²á: 2013-08-18
- ÐÔ±ð: GG
- רҵ: Ö×Áö»¯Ñ§Ò©ÎïÖÎÁÆ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï
cainiaodui(RXMCDM´ú·¢): ½ð±Ò+1, ¶àлӦÖú£¡ 2014-01-10 01:22:40
cainiaodui(RXMCDM´ú·¢): ½ð±Ò+1, ¶àлӦÖú£¡ 2014-01-10 01:22:40
|
Predictive biomarkers produced by the tumor or expressed within the tumor vessels that confer sensitivity to Dll4-Notch blockade have not yet been identified. A useful starting point may be to assume that high levels of Dll4-Notch are correlated with sensitivity to pathway inhibition. Thus, further analysis of the expression levels of various components of the Delta-Notch signaling pathway in clinical specimens will be useful. ÓÉÖ×ÁöÉú³É»òÔÚÖ×ÁöѪ¹ÜÄÚ±í´ï£¬¿É¸³ÓèDll4-Notch·âËøµÄÃô¸ÐÐÔµÄÔ¤²âÐÔÉúÎï±êÖ¾ÎïÉÐδ±»Ê¶±ð¡£ÓÐÒ»ÖÖ¿ÉÄܾÍÊǸߺ¬Á¿µÄDll4-NotchÓ°ÏìͨµÀÒÖÖÆµÄÁéÃô¶È¡£Òò´Ë£¬ÔÚÁÙ´²±ê±¾ÖнøÒ»²½µÄ¼ì²âDelta-Notch¸÷¸ö×é·ÖÐźÅͨµÀµÄÐźűí´ïˮƽ½«ËµÃ÷ÎÊÌâ¡£ ÒµÓàˮƽ£¬Â¥Ö÷²Î¿¼¡£ ½«ÊÇÓÐÒæµÄ¡£ |
4Â¥2013-10-29 17:05:05














»Ø¸´´ËÂ¥